Burosumab in Children and Adolescents With X-linked Hypophosphatemia

Summary

In this prospective longitudinal cohort study we studied the efficacy and safety of burosumab in real-clinical practice for \<13- and \>13-years old children affected with X-linked hypophosphatemia. 57 children with XLH were switched from conventional treatment to burosumab. After 12 months we assessed the efficacy and safety of treatment with burosumab on the whole cohort and separately on the cohort of \>13-years old adolescents.

Timeline

Start

2018-03-18

Primary completion

2019-03-20

Completion

2022-09-16

Drugs

Indications